Log in Free sign up

Immunocore (IMCR) News and press releases

News

From Benzinga Pro

Immunocore Holdings Q1 EPS $(0.48) Up From $(1.04) YoY, Sales $29.60M Up From $11.41M YoY

Immunocore Holdings (NASDAQ:IMCR) reported quarterly losses of $(0.48) per share. This is a 53.85 percent increase over losses of $(1.04) per share from the same period last year. The company reported $29.60 million in

Immunocore Eye Cancer Cell Therapy Scores European Approval

Biotech, News, Health Care, Small Cap, General

The European Commission (EC)

The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO

Biotech, Earnings, News, Penny Stocks, Small Cap, General

Here's a roundup of top developments in the biotech space over the last 24 hours:

Immunocore Holdings Q4 EPS $(1.21), Sales $8.90M

Immunocore Holdings (NASDAQ:IMCR) reported quarterly losses of $(1.21) per share. The company reported $8.90 million in sales this quarter.

The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision

Biotech, Earnings, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, General

Here's a roundup of top developments in the biotech space over the last 24 hours.

Press releases

From Benzinga Pro

Immunocore to present at Oppenheimer's 32nd Annual Healthcare Conference

News, Press Releases

Immunocore to present at Oppenheimer's 32nd Annual Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 March 2022) Immunocore Holdings Plc (NASDAQ:IMCR), a commercial-stage

Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma

PRESS RELEASE Immunocore receives positive CHMP opinion for KIMMTRAK® (tebentafusp) for the treatment of unresectable or metastatic uveal melanoma If approved by the European Medicines Agency, KIMMTRAK will be